Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells by Weiskopf, D. et al.
Comprehensive analysis of dengue virus-specific
responses supports an HLA-linked protective role
for CD8+ T cells
Daniela Weiskopfa, Michael A. Angeloa, Elzinandes L. de Azeredoa, John Sidneya, Jason A. Greenbauma,
Anira N. Fernandob, Anne Broadwaterc, Ravi V. Kollaa, Aruna D. De Silvaa,b, Aravinda M. de Silvac, Kimberly A. Mattiad,
Benjamin J. Doranzd, Howard M. Greya,1, Sujan Shrestaa, Bjoern Petersa, and Alessandro Settea,1
aDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037; bGenetech Research Institute, Colombo 00800, Sri Lanka;
cDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27599; and dIntegral Molecular,
Philadelphia, PA 19104
Contributed by Howard M. Grey, March 19, 2013 (sent for review January 22, 2013)
The role of CD8+ T cells in dengue virus infection and subsequent
diseasemanifestations is not fully understood. According to the orig-
inal antigenic sin theory, skewing of T-cell responses induced by
primary infection with one serotype causes less effective response
upon secondary infection with a different serotype, predisposing
individuals to severe disease. A comprehensive analysis of CD8+
responses in the general population from the Sri Lankan hyperen-
demic area, involving the measurement of ex vivo IFNγ responses
associated with more than 400 epitopes, challenges the original an-
tigenic sin theory. Although skewing of responses toward primary
infecting viruses was detected, this was not associated with impair-
ment of responses either qualitatively or quantitatively. Furthermore,
wedemonstratehighermagnitudeandmorepolyfunctional responses
for HLA alleles associated with decreased susceptibility to severe dis-
ease, suggesting that a vigorous response by multifunctional CD8+
T cells is associated with protection from dengue virus disease.
Dengue virus (DENV) is the etiologic agent of dengue fever(DF), the most significant mosquito-borne viral disease in
humans.Disease can be caused by any of the fourDENV serotypes
(DENV1 to -4), which share 67–75% sequence homology with one
another (1). DENV transmission occurs in more than 100 coun-
tries and is an increasing public health problem in tropical and
subtropical regions (2). Demographic changes, urbanization, and
international travel contribute to the expansion of geographical
areas where transmission occurs, and all four DENV serotypes are
now circulating in Asia, Africa, and the Americas (3, 4). Up to 100
million DENV infections occur every year (5), and severity can
range from asymptomatic to an acute self-limiting febrile illness
(DF). In a small proportion of patients, the disease can exacerbate
and progress to dengue hemorrhagic fever (DHF) and/or dengue
shock syndrome (DSS), characterized by severe vascular leakage,
thrombocytopenia, and hemorrhagic manifestations (4).
Although natural infection by any of the four DENV serotypes
(primary infection) produces a lasting protective immunity against
reinfection by the same serotype, it does not protect against
infections with other serotypes (secondary infections) (6, 7). Epi-
demiologic studies have shown that themajority of individuals that
develop DHF/DSS had been previously infected with a different
serotype (8). Consequently, the development of DENV vaccines
has been hampered by the potential risk of vaccine-related adverse
events and the requirement to induce long-lasting protective im-
mune responses against all four DENV serotypes simultaneously
(9). The cause for the increased frequency of DHF following
secondary infections has not been fully elucidated. One hypothesis
is that serotype cross-reactive antibodies exacerbate disease by
increasing infection of cells bearing Fcγ receptors, resulting in
higher viral loads and more severe disease via this antibody-
dependent enhancement (ADE) of infection (10, 11). Indeed,
nonhuman primate and murine models have demonstrated that
antibodies can lead to enhancement of DENV infection and
disease in vivo (12–15).
Another hypothesis postulates that T cells raised against the first
infecting serotype dominate during a secondary heterologous in-
fection in a phenomenon termed “original antigenic sin” (16, 17).
This term was first applied to the humoral response to influenza
epidemics (18) but has also been observed inCD8+T-cell responses
against lymphocytic choriomeningitis virus (19). This hypothesis
postulates that, during secondary infection, expansion of preexisting
lower avidity cross-reactive memory T cells dominate the responses
over that of naïve T cells that are of higher avidity for the new
DENV serotype. This expansion of low avidity T cells results in less
efficient elimination of DENV-infected cells.
A role for T cells in control of DENV infection is suggested by
several studies that implicate HLA associations as a genetic com-
ponent to variable susceptibility to DENV disease (20–26). How-
ever, it has not been addressed whether these associations might
indicate a positive or detrimental role for T-cell responses. One
major obstacle to the elucidation of the function of T cells is the
lack of a comprehensive characterization ofHLA-restrictedDENV
responses in the context of natural infection.
Herein, we present a comprehensive analysis of functional T-cell
memory against DENV and are able to correlate this with HLA al-
leles expressed in the very same donors. Collectively, the data sug-
gest an HLA-linked protective role of CD8+ T-cell responses and
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do not support a causative role for CD8+ T cells in the induction of
severe disease following secondary heterologous infection.
Results
Effective Coverage of the General Population from the Colombo
Endemic Area. We aimed to define the T-cell memory response
against DENV in a donor population derived from an endemic
area. For a broad coverage, we selected a panel of HLA A and
HLA B alleles that includes any allele present with a frequency of
4.5% (HLAA) or 5% (HLAB) in both the general population and
that of Sri Lanka. Thus, we have collected and subsequently HLA
typed peripheral blood mononuclear cells (PBMCs) from 250
healthy adult blood donors from the National Blood Center,
Ministry of Health, Colombo, Sri Lanka. The 27 selected alleles
allowed matching at least 3 out of 4 possible HLA A and B alleles
expressed per donor in 90% of our cohort (3 out of 4 in 41% and 4
out of 4 in 49%, respectively, Fig. 1A, black bars and solid line).
Considering closely related HLA alleles within the same supertype
(27), the allelic coverage of at least 3 of 4 MHC class I alleles in-
creased to 99% of the donors (Fig. 1A, white bars).
Immunodominant Regions of the DENV Polyprotein. PBMCs from all
donors were screened with pools of predicted HLAmatched class I
binding peptides covering all four serotypes in IFNγ enzyme-linked
immunosorbent spot (ELISPOT) assays. Ex vivo reactivity was
detected for 22%of primary and 43%of secondarydonors (Fig. 1B).
By definition, primary cases showed antibody neutralization for only
one serotype whereas secondary cases are individuals with anti-
bodies capable of neutralizingmore than one serotype. The average
response per donor, as well as the average number of epitopes
detected, was higher in donors who had experienced secondary in-
fection compared with primary infection. In total, 753 donor/pep-
tide responses were identified, corresponding to 408 unique CD8+
T-cell epitopes. A complete list of these epitopes is available on the
ImmuneEpitopeDatabase (www.iedb.org; submission ID1000504).
To investigate the relative immunodominance of different parts of
the DENV proteome, we plotted response magnitude [as spot
forming cells (SFCs) per 106 PBMC values] and frequency of
responding donors (as a heat map) as a function of the genomic
position ofDENVproteins (Fig. 2A). Nonstructural (NS) proteins
3, 4B, and 5 were the most vigorously and frequently recognized
proteins and accounted for more than two thirds of the total re-
sponse. Conversely, proteins known to be main antibody targets NS
protein 1 and Envelope (E) were less prominently recognized by
CD8+ T cells.
Clustering of these epitopes based on sequence identity
greater than 80% resulted in the definition of 267 antigenic
regions. The 25 most antigenic regions accounted for half of the
total response (Fig. 2B). Several of these regions contained
epitopes derived from multiple serotypes and restricted by a va-
riety of different alleles. The sequences, proteome location, se-
rotype affiliation, HLA restriction, frequency, and magnitude of
responses of these 25 immunodominant antigenic regions are
shown in Table 1.
Differences Between Serotype-Specific Responses. The data were
next analyzed as a function of different serotype reactivity. At the
same time,we categorizedT-cell reactivity on the basis ofwhether it
was directed against serotype-specific sequences (found only in one
serotype) or against conserved/homologous sequences (sequences
found in two or more serotypes, allowing a single residue sub-
stitution to account for potential cross-reactivity of highly homol-
ogous sequences). Conserved sequences accounted for 37% of the
overall responses in our cohort. With respect to serotype-specific
responses, responses against DENV2-derived epitopes were by far
most prevalent (42%), followed by DENV3 (12%), DENV4 (6%),
and DENV1 (3%).
Next, for each of the four serotypes, we compiled responses
from donors exhibiting responses against serotype-specific epito-
pes, used as an indicator of previous infection with that specific
serotype. The responses of donors who responded to serotype-
specific and/or conserved epitopes are shown in Table 2. No sig-
nificant difference in total magnitude of responses was noted be-
tween the groups (P > 0.108 for any pairwise comparison). On
average, donors recognizing DENV2-specific epitopes elicited a
T-cell response of 1,987 SFCs per 106 PBMCs against serotype-
specific and 822 SFCs per 106 PBMCs against conserved epitopes,
corresponding to a ratio of 2.4, showing that the majority of
responses in these donors were directed against serotype-specific
regions (Table 2, see “Secondary infection” column). The knowl-
edge of the origin of epitopes allowed interpreting the data in
context of the epidemiological history of Sri Lanka. The known
historical prevalence of DENV serotypes circulating in Sri Lanka
indicates that, whereas DENV2 has historically always been
prevalent in Sri Lanka, recent years have seen the appearance of
new substrains of DENV3 Lanka (28, 29), and DENV1 has only
Fig. 1. HLA coverage and T-cell reactivity of the study population. (A) HLA allele coverage in the Sri Lankan cohort is shown. Bars represent the relative
number of donors in which the donor-specific HLA alleles have been exactly matched (filled bars) or matched within the same supertype (open bars) with the
27 alleles selected for our study. The black line represents the cumulative number of donors in which 1–4 alleles have been matched exactly. (B) T-cell re-
activity in blood donors after primary (n = 55; open bars) and secondary infection (n = 127; filled bars) with DENV. Shown are the relative response frequency
(Left), the average magnitude of responses per donor (Center), and the average number of epitopes per donor (Right).























recently appeared in this population (30). Accordingly, we hy-
pothesized that original antigenic sin should dictate that the ratio of
serotype specific to conserved responses should be decreased when
comparing DENV2 (the “original” antigen) with other serotypes.
As predicted by this reasoning, the overall response of donors
recognizing serotype-specific regions of either DENV1 orDENV3
was significantly skewed toward conserved regions, reflected by the
ratio of specific vs. conserved responses of 0.3 and 0.6 for DENV1
and DENV3, respectively (P = 0.037 for DENV1 and P = 0.028
for DENV3 in a Mann–Whitney test). The same trend, albeit not
statistically significant (P = 0.079), for a difference in the ratio of
serotype-specific/conserved epitopes was observed in the case
of DENV4.
Analysis of the primary infection donors who showed T-cell
reactivity against serotype-specific and/or conserved epitopes, al-
though not significant due to low numbers, further supports the
notion that, following primary infection, serotype-specific respon-
ses dominate over conserved ones and that the shift to a focus on
conserved epitopes is a result of secondary infection (Table 2, see
“Primary infection” column). Accordingly, the dominance of con-
served epitopes in DENV3 and DENV1 responses likely reflects
previous DENV2 infection, and thus expansion of T cells recog-
nizing conserved epitopes during secondary infection (original
antigenic sin).
Original Antigenic Sin Is Not Associated with Differences in Avidity or
Multifunctionality of T-Cell Responses. These observations allowed
us to test whether original antigenic sin was associated with dif-
ferential quality or quantity of response (differences in magnitude,
avidity, and types of cytokines made). Accordingly, pools of pep-
tides corresponding to either serotype-specific or conserved epit-
opes were tested in intracellular cytokine staining (ICS) assays with
several representative donors (Fig. 3). No appreciable difference in
the magnitude, phenotype, pattern of multifunctionality, or avidity
of the T-cell responses between serotype-specific and conserved
responses was detected (Fig. 3A, B,D, and F, respectively). In both
groups, the majority of the DENV-specific T cells displayed an
effector memory phenotype (CD45RA−CCR7−; 42% and 44% for
conserved and specific, respectively), followed by central memory
(CD45RA−CCR7+; 24%) and T cells: Effector Memory re-
expressing CD45RA (TEMRA) (CD45RA
+, CCR7−; 26% and
25%) (Fig. 3C, Left). The expression levels of CD27 and the
marker for cytotoxicity CD107a were also comparable (Fig. 3C,
Center and Left). In terms of cytokine expression patterns, no
difference between serotype-specific and conserved responses was
detected (Fig. 3D). Seventeen percent of cells responding to se-
rotype-specific pools were positive for all three cytokines tested
(IFNγ, TNFα, and IL2), compared with 15% of cells responding
to conserved pools. The majority of responding cells were double
positive for two cytokines (50% and 54%, respectively), followed
by cells positive for only one cytokine (33% and 21%) (Fig. 3E).
Low Magnitude T-Cell Responses Are HLA-Linked and Associated with
Disease Susceptibility. Previous studies have highlighted that certain
HLA alleles are associated with either increased or decreased risk
of clinical manifestations. To investigate this issue further, we cor-
related HLA types expressed in our cohort with T-cell responses.
Fig. 4A shows the frequency (black bars) and the magnitude (white
bars) of T-cell responses sorted according to their HLA restriction
element. A wide variation in terms of frequency andmagnitude was
detected as a function of the different HLA alleles. Interestingly,
certain alleles were associated with low response frequency and
magnitude (e.g., A*0101, A*2402), whereas others were associated
with high response frequency and magnitude (B*0702, B*3501).
Still other alleles were associated with low frequency and high
magnitude response (B*4001), and conversely others were associ-
ated with high frequency and low magnitude response (A*2601).
Overall, HLA B restricted responses were of significantly higher
magnitude, but not frequency, compared with HLA A restricted
responses (P = 0.036 and P = 0.113, respectively in an unpaired
t test). To test whether T-cell responses correlated with HLA-
associated disease susceptibility, we compiled all data available in
the literature (20–26) and performed a metaanalysis as described in
Materials and Methods. When we compared average magnitudes of
HLA restricted responses with disease susceptibility, it was found
that weak T-cell responses correlated with disease susceptibility
(Fig. 4B, Left; P = 0.05). This correlation was accounted for by
the response magnitude rather than frequency (Fig. 4B, Center;
P = 0.04). Further analysis revealed that the magnitude per
epitope, rather than the breadth of responses, correlated best
with disease susceptibility (Fig. 4B,Right; P=0.02), such that low
T-cell responses were associated with disease susceptibility.
A possible explanation for these observations is that alleles
associated with higher magnitude responses may in turn be as-
sociated with higher degrees of multifunctionality, most benefi-
cial in protecting from disease. A detailed analysis of cytokines
produced by DENV-specific T cells revealed that, indeed, high
magnitude responses were associated with a greater proportion
of multifunctional T-cell responses. The response hierarchy was
IFNγ > TNFα > IL2 in all experiments (Fig. 4C).
Discussion
The role of CD8+ T cells in DENV infection is not yet fully
understood. Although in animal models CD8+ T cells are asso-
ciated with protection from infection and disease (31, 32), pre-
vious studies in humans suggest that T cells are associated with
pathogenesis according to the original antigenic sin hypothesis
(17, 33). Although definitions vary somewhat, original antigenic
Fig. 2. Immunodominant regions of the DENV polyprotein. (A) The genomic position of DENV-encoded proteins (C, capsid; prM, premembrane; M, mem-
brane; E, envelope, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) and the total observed response magnitude for every amino acid along the proteome is
shown (filled bars). The data are expressed as total number of IFNγ SFCs per 106 PBMCs. The heat map indicates the number of donors that showed a positive
cytokine response to peptides within these regions. (B) Identified antigenic regions were plotted as a function of the percentage of the total response. Lines
indicate the number of regions needed to account for 50%, 75%, and 90% of the total response, respectively.
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sin in the context of DENV infection is usually defined as the
imprint of responses associated with primary infection of a given
serotype, which shapes and biases responses following a second-
ary infection with a different serotype toward epitopes shared by
the two serotypes (34). Herein, we show that, whereas the pre-
dicted outcome of original antigenic sin can be detected in the
general population from Sri Lanka, its consequence is not to
generate a less functional response, but rather it results in honing
responses toward recognition of conserved viral sequences. We
further show that different HLA alleles are associated with dif-
ferential magnitude of anti-DENV responses, and that HLA
alleles known to be associated with increased risk of severe DENV
disease (22, 24) are associated with weaker CD8+ responses.
Furthermore, the higher magnitude responses are associated with
more polyfunctional CD8+ T cells. Taken together, these data
support a protective role for CD8+ T cells and challenge the
notion that DENV-associated pathogenicity is a result of original
antigenic sin.













1 TPEGIIPAL 1978 1,4 B*0702 1 183 10,671
TPEGIIPALF 1978 1,4 B*3501 9 2,213
TPEGIIPSM 1978 2 B*3501, B*5301 5 2,717
TPEGIIPSMF 1978 2 B*0702, B*3501 7 1,772
TPEGIIPTLF 1978 4 B*3501,B*0702,
B*5301
11 2,914
YTPEGIIPTL 1977 4 A*0206 1 872
2 GEARKTFVDL 2005 2 B*4001 3 1,405 5,005
GEARKTFVEL 2005 1 B*4001 3 1,330
GEQRKTFVEL 2005 4 B*4001 2 1,050
GESRKTFVEL 2005 3 B*4001 3 1,220
3 LPVWLAHKVA 2020 3 B*3501 1 23 4,157
LPVWLAYKV 2020 2 B*5301, B*5101 2 923
LPVWLAYKVA 2020 2 B*3501 7 2,427
LPVWLAYRVA 2020 2 B*5101 1 470
LPVWLSYKV 2020 1 B*5101 1 313
4 HPGAGKTKRY 1672 2 B*3501 10 3,047 3,047
5 NPEIEDDIF 1653 2 B*3501 10 3,390 3,390
6 DTTPFGQQR 2840 1,2,3,4 A*6801, A*3301 8 3,260 3,260
7 MSFRDLGRVM 1176 2 B*3501 8 3,250 3,250
8 ATGPILTLW 2444 4 B*5801 2 938 3,089
ATGPISTLW 2444 2 B*5801 2 236
ATGPITTLW 2444 3 B*5801 1 505
ATGPLTTLW 2444 1 B*5801 1 275
ATGPVLTLW 2444 4 B*5801 2 390
LATGPVLTLW 2443 4 B*5301 1 745
9 CLIPTAMAF 108 4 B*1501 1 67 2,815
MLIPTAMAF 108 2 B*3501 7 2,748
10 VATTFVTPM 2290 2 B*3501 8 2,777 2,777
11 KPRICTREEF 2885 1 B*0702 1 340 2,756
KPRLCTREEF 2885 3 B*0702 1 350
NPRLCTREEF 2885 4 B*0702 1 365
RPRLCTREEF 2885 3 B*0702 4 501
TPRMCTREEF 2885 2 B*0702, B*3501 5 1,200
12 VPLLAIGCY 2338 2 B*3501 7 1,520 2,603
VPLLAMGCY 2338 4 B*3501 1 1,083
13 MSYSMCTGKF 578 2 B*3501 6 2,553 2,553
14 DPASIAARGY 1768 1,2,3 B*3501 9 2,383 2,383
15 IANQATVLM 2315 2 B*3501 7 1,518 1,518
16 APTRVVAAEM 1700 2,3,4 B*0702, B*3501 8 1,623 2,230
APTRVVASEM 1700 1 B*0702 5 607
17 TPMLRHTIEN 2296 3,4 B*0702 2 388 2,123
18 MLVTPSMTM 274 3 B*3501 8 1,735 1,735
19 FTMRHKKATY 2738 2 B*3501 4 1,723 1,723
20 FTILALFLAH 248 3 B*3501 8 1,715 1,715
21 WHYDQDHPY 2787 2 B*3501 5 1,628 1,628
22 MALKDFKEF 2083 4 B*3501 7 1,497 1,497
23 LMKITAEWLW 2868 2 B*5301 1 423 1,417
MEITAEWLW 2869 3 B*5801 1 583
VMGITAEWLW 2868 3 B*5301 1 410
24 TETTILDVDL 2266 4 B*4001 2 1,413 1,413
25 GEFRLRGEQR 1999 4 B*4001 3 1,373 1,373























Before this study, only a few CD8+ T-cell epitopes have been
defined, and lack of knowledge of T-cell epitopes presented by
common MHC alleles expressed by populations in endemic areas
allowed only an episodic evaluation of responses. In this study,
we report a comprehensive ex vivo characterization of HLA re-
stricted DENV-specific T-cell memory in the general population
of Sri Lanka. The impact of these results can be appreciated by
noting that previous studies, as compiled by the Immune Epitope
Database (IEDB; www.iedb.org), identified a total of 82 unique
CD8+ T-cell epitopes. This study expands this number by almost
fivefold. Twenty-five main antigenic regions could account for
about 50% of the responses. This relatively small number pro-
vides a future tool to further investigate the CD8+ responses in
small sample volumes typically available from acute fever patients
and/or children.
Consistent with the known epidemiologic history of DENV in-
fection in Sri Lanka (28–30) and the notion of original antigenic
sin, we see that, whereas serotype-specific responses predominate
forDENV2, there is a shift toward conserved epitopes forDENV3
and DENV1 responses, compatible with the epidemiologic data
that indicate that initial infection is most likely caused by DENV2
and thus expansion of T cells recognizing conserved epitopes
following infection with the more recently prevalent serotypes
DENV1 and -3. In the case of DENV4, the same trend, albeit not
statistically significant, was observed. Also, DENV4 is the most
divergent serotype (35) and thus shares less conserved regions
with other DENV serotypes, whichmight further contribute to the
somewhat increased response to serotype-specific epitopes.
These observations provided an opportunity to test whether
antigenic sin was associated with lower quality of responses at the
level of the general population from an endemic region. No sig-
nificant difference in the magnitude, phenotype, pattern of mul-
tifunctionality, or avidity of the T-cell responses between serotype-
specific and conserved/homologous responses was detected. It has
been shown that CD8+ T cells acquire activation markers, pro-
liferate actively, and express cytotoxic molecules during infection,
directly contributing to the killing of infected cells (36, 37). Addi-
tionally, strong responses were associated with multifunctionality,
Table 2. Differences between serotype specific responses in
primary and secondary infections
Infection Serotype n
Average T-cell response/donor
Total Specific Conserved Ratio
Secondary
infection
DENV1 18 957 ± 310 206 751 0.3
DENV2 30 2,819 ± 1,203 1,987 822 2.4
DENV3 22 2,032 ± 619 766 1,266 0.6
DENV4 20 2,399 ± 789 1,124 1,275 0.9
Primary
infection
DENV1 5 167 ± 58 111 56 1.9
DENV2 0 0 0 0 0
DENV3 2 443 ± 37 389 54 7.2
DENV4 1 27 27 0 —
Fig. 3. Comparison between responses to conserved and serotype-specific epitopes. Representative donors who had been secondarily infected previously were
incubated with donor-specific peptide pools (1μg/mL) originated either from regions serotype-specific for DENV3 (open circles) or regions conserved between
two or more other serotypes (filled circles) for 6 h in the presence of brefeldin A. Cells were then stained with mAB against surface markers CD3, CD8, CD45RA,
and CD27 andmAB against intracellular CD107a, IFNγ, TNFα, and IL2. Magnitude of response (A) and phenotype of responding cells (B) of the individual donors
(n = 7) based on gating of the IFNγ producing cells are shown. The average CD45RA, CCR7, CD27, and CD107a expression for all responding cells is shown in C.
Multifunctional responses are shown for individual donors (D) and as the average of all donors studied (E, n = 6). Avidity of responding T cells was determined by
incubating PBMCs with ascending concentrations of peptide pools (0.001, 0.01, 0.1, 1, and 10 μg/mL). The peptide concentration necessary to induce 50% of the
maximum responses (EC50) was calculated, and the average EC50 was compared between the conserved and serotype-specific epitopes (F).
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which has been shown to be a main predictor of immunity in other
viral systems (38, 39).
The evidence revealed by the current study is more aptly de-
scribed by maturation of the specificity of CD8+T-cell responses,
induced by repeated stimulation with partially or completely cross-
reactive antigens. The protective role of T cells in humans was
supported by this study and reverberates with renewed urgency
and newsworthiness in light of a recent phase 2b proof-of-concept
efficacy vaccine trial (40) that showed only 30% overall efficacy,
demonstrating partial (60–80%) protection toward 3 of 4 DENV
serotypes, with no protection against DENV2 infection despite
three subsequent immunizations and high neutralization titers
against all four serotypes.Our demonstration of the protective role
of T-cell responses, dominantly targeting the nonstructural pro-
teins NS3, NS4B, and NS5, which are absent in the recombinant
live, attenuated tetravalent dengue-yellow fever chimeric virus
vaccine (41), both provides an explanation for these disappointing
results and underlines the broad relevance of our study.
Our observations are in contrast to other studies that reported
that humans who contract a secondary dengue infection generate
a CD8+ T-cell response that recognizes a previously encountered
dengue serotype with low avidity, which was hypothesized to
contribute to pathogenesis (17). This hypothesis, however, is also
in conflict with the observation that heterologous T-cell responses
are not needed to produce DHF in infants, and the same severe
vascular permeability clinical syndrome, and the same concen-
trations of cytokines in blood, are produced during primary dengue
immune responses in infants, as they are in children with secondary
Fig. 4. HLA-linked T-cell responses. (A) Differential frequency and magnitude of HLA restricted responses in dengue-seropositive donors (n = 182). Frequency
(filled bars) and the magnitude (open bars) of T-cell responses (as total SFCs per 106 PBMC values) sorted according to their restriction element are shown. (B)
Association of HLA restricted T-cell responses with disease susceptibility. Disease susceptibility was correlated with the average magnitudes of HLA restricted
responses (Left), with the frequency and the magnitude of T-cell responses per donor (Center) and with the magnitude per epitope as well as breadth of re-
sponse (Right). One-tailed Spearman test was then used to calculate correlations. The best positive correlationwas observedwith themagnitude of response per
epitope (P = 0.02). (C) Multifunctionality of HLA restricted responses. Representative donors were stimulated with HLA restricted donor-specific peptide pools
for 6 h in the presence of BFA. Cells were then stained with mAB against surface markers CD3 and CD8 and mAB against intracellular IFNγ, TNFα, and IL2. Pie
charts represent cytokine profiles of individual donors. The relative number of cells producing one (dark gray areas), two (light gray areas), or three (white areas)
of themeasured cytokines is shown. Percentages in the pie charts represent the relative number of cells that produce two ormore cytokines. Numbers under the
pie charts represent the T-cell responses (as IFNγ SFCs per 106 PBMCs) of this specific donor/allele combination in the ELISPOT assay (n = 4).























dengue infections (42). Indeed, a recent study has shown a tem-
poral mismatch between the CD8+ T-cell response and com-
mencement of capillary leakage, suggesting that CD8+ T cells are
not responsible for early triggering of capillary leakage in children
with DHF (37).
Multiple HLA class I alleles have been associated with either
protection or susceptibility to dengue infection (22, 23, 25, 26).
HLA A*24 is associated with susceptibility to disease not only in
secondary, but also in primary infections with DENV (22, 24), and
a recent report associated HLA A*01 with susceptibility to DHF
in a Brazilian population (43). In contrast, B*3501 was negatively
associated with symptomatic disease in Mexican dengue fever
patients (25), and one study reported that HLAA and not HLA B
genes are associated with DHF (22). However, until now, it was
not clear whether this association reflected differences in the
corresponding T-cell responses. In our experiments, A*0101 and
A*2402 restricted responses were among the lowest observed in
terms of frequencies as well as magnitude whereas B*3501 re-
stricted responses were associated with highmagnitude responses.
Additionally, strong responses were associated with multi-
functionality, which has been shown to be an important predictor
of immunity in other viral systems (38, 39). Furthermore, higher
frequencies of DENV-specific IFNγ-producing T cells are present
in children who subsequently developed subclinical infection,
compared with those who develop symptomatic secondary DENV
infection (44).
We are aware that our data relate to the features of immunity
present in the general population and do not directly address the
features that may be present at the time of acute manifestations
such as DHF and DSS. Thus, although our data demonstrate that
secondary infection does not negatively affect the response at the
level of the general population, one could speculate a pathogenic
role for T cells in the relatively few individuals that develop DHF
or DSS (17). For example, the presence of disease-enhancing
antibodies together with the HLA-linked lack of a multifunctional
T-cell response might be responsible for immune linked patho-
genesis in these individuals. This hypothesis would explain why
only a small subset of individuals, the ones who carry non-
protective HLA alleles, develop severe disease in secondary in-
fection with DENV. This approach combines the two major
hypotheses, ADE and T-cell–mediated pathogenesis in one
model and points the way forward to identify robust correlates of
protection in natural immunity and vaccination against DENV.
Materials and Methods
Selection of DENV Sequences.We retrieved 2,376 (984 DENV1, 795 DENV2, 493
DENV3, and 101 DENV4) full-length DENV polyprotein sequences for each
serotype from the National Center for Biotechnology Information Protein
database using the following query: txid11053[orgn] AND 3000:5000[slen].
The number of sequences available varied drastically as a function of geo-
graphic locations. To ensure a balanced representation, the number of iso-
lates by geographical region was limited to a maximum of 10. Sequences
were considered “unique” if they varied by at least 1 amino acid from all
other sequences. In total, 162 DENV1, 171 DENV2, 169 DENV3, and 53
DENV4 sequences were selected. Polyproteins were broken down into all
possible 9- and 10-mer sequences for binding predictions as described below.
MHC Class I Binding Predictions and Peptide Selection. All 9- and 10-mer
peptideswerepredicted for theirbindingaffinity to27MHCclass Imolecules.A
panel of 16 HLA A (A*01:01, A*26:01, A*32:01, A*02:01, A*02:03, A*02:06,
A*68:02, A*2301, A*24:02, A*03:01, A*11:01, A*30:01, A*31:01, A*33:01,
and A*68:01) and 11 HLA B alleles (B*40:01, B*44:02, B*44:03, B*57:01,
B*58:01, B*15:01 B*07:02, B*35:01, B*51:01, B*53:01, and B*08:01) were se-
lected, which account for 97% of HLA A and B allelic variants in most eth-
nicities (45). Binding predictions were performed using the command-line
version of the consensus prediction tool available on the IEDBweb site (www.
iedb.org) (46). For each allele and length combination, peptides from each
included polyprotein were selected if they were in the top 1% of binders in
a given strain and they existed in at least 30%of the isolates for that serotype.
Homologous peptides from two or more serotypes that were predicted to
bind to one HLA molecule were placed in the “conserved peptides” group.
This analysis resulted in the synthesis of 8,088 peptides (Mimotopes), which
were subdivided into pools of 10 individual peptides.
Human Blood Samples. We obtained 250 peripheral blood samples from
healthy adult blood donors from the National Blood Center, Ministry of
Health (Colombo, Sri Lanka) in an anonymous manner. The institutional
review boards (IRBs) of both the La Jolla Institute for Allergy and Immu-
nology (LIAI) and the Medical Faculty, University of Colombo (serving as
National Institutes of Health-approved IRB for Genetech) approved all
protocols described in this study. Donors were of both sexes and between 18
and 60 y of age. Sampleswere collected over a time course of 19mobetween
February 2010 and August 2011. PBMCs were purified by density gradient
centrifugation (Ficoll-Paque Premium; GE Healthcare Biosciences) resus-
pended in FBS (Gemini Bio-Products) containing 10% dimethyl sulfoxide,
and cryo-preserved in liquid nitrogen. Twenty-three of the 250 blood
samples obtained from the National Blood Center had to be excluded from
the study due to poor viability of cells after shipment to LIAI. Genomic DNA
isolated from PBMCs of the study subjects by standard techniques (QIAmp;
Qiagen) was used for HLA typing. High resolution Luminex-based typing for
HLA class I was used according the manufacturer’s protocol [Sequence-
Specific Oligonucleotides (SSO) typing; One Lambda]. Where needed, PCR-
based methods were used to provide high resolution subtyping [Sequence-
Specific Primer (SSP) typing; One Lambda).
Serology. For the 227 samples included in the study, DENV seropositivity was
determined by dengue IgG ELISA as previously described (28). In Sri Lanka,
levels of seropositivity for DENV approach 70% by the age of 10 (47), and
DENV-specific IgG ELISAs confirmed that 80% of the donors in our cohort
were seropositive (182 out of 227). Flow cytometry-based neutralization
assays were performed for further characterization of seropositve donors, as
previously described (48). Neutralization assays determined that 127 donors
have experienced infection with more than one serotype, further referred to
as secondary infections. The primary cases demonstrated that all four sero-
types circulate in Sri Lanka (14 DENV1, 18 DENV2, 20 DENV3, and 3 DENV4
donors), confirming previous reports (29).
Ex Vivo IFNγ ELISPOT Assay. PBMCs (2 ×105) were incubated in triplicates with
0.1 mL of complete RPMI 1640 in the presence of HLA-matched peptide
pools (2 μg/mL) as previously described. Following a 20-h incubation at 37 °C,
the cells were incubated with biotinylated IFNγ mAb (mAb 7-B6-1; Mabtech)
for 2 h and developed as previously described (49).
Epitope Cluster Analysis. All epitopes identified were clustered using the
Epitope Cluster Analysis tool from the IEDB Web site (www.iedb.org). This
tool groups epitopes into clusters based on sequence identity. A cluster is
defined as a group of sequences that have a sequence similarity greater than
the minimum sequence identity threshold specified. The threshold of mini-
mum sequence identity used in this study was set at 80%.
Meta Analysis for HLA Associations. To test whether T-cell responses corre-
lated with HLA-associated disease susceptibility, we compiled all data
available in the literature (20–26). For each of the studies, we ranked all
investigated alleles according to their association with clinical manifes-
tations (DF, DHF, and DSS; Dataset S1). We then calculated a percentile
ranking across all studies for the 18 alleles detected in significant frequen-
cies in our own cohort and correlated the rankings with T-cell responses.
Flow Cytometry and ICS. The following monoclonal antibodies from eBio-
science were used in this study: anti-CD8a PerCP-Cy5.5 (clone RPA-T8), anti-
CD3 efluor 450 (clone UCHT1), anti-CD107a FITC (clone ebioH4A3), anti-
CD45RA PE-CY7 (clone H100), anti-CD27 PE (clone o323), anti-CD197 (CCR7)
APC efluor 780 (clone 3D12), anti-IFNγ APC (clone 4SB3), anti-IL 2 PE (clone
MQ1-17H12), and anti-TNFα (clone MAD 110). PBMCs were cultured in the
presence of peptide pools (10 μg/mL) and GolgiPlug containing brefeldin A
(1 μg/mL) (BD Biosciences). Cells were then washed and stained for 30 min on
ice, fixed with 1% of paraformaldehyde (Sigma-Aldrich), and kept at 4 °C
overnight. Samples were acquired on an LSR II flow cytometer (BD Immu-
nocytometry Systems) and analyzed with FlowJo software (Tree Star).
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